ADAG Stock — Adagene Inc

Adagene Inc (ADAG)

Updated October 16, 2026.

ADAG is a Stock. Total return is -93.1% over the past 5.7 years, 204.3 points behind SPY at 111.2%.

Adagene Inc. is a clinical-stage biotechnology company developing monoclonal antibody drugs for cancer treatment, primarily focused on the Chinese market. The company has multiple candidates in clinical trials, including lead programs targeting CTLA-4, PD-L1, and CSF-1R, along with earlier-stage bispecific antibody programs in preclinical development. As a pre-revenue biotech company, it does not currently have an established distribution history.

ADAG performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.1% over the past 5.7 years, 204.3 points behind SPY at 111.2%. Over the past year its total return — price change plus distributions reinvested — is 15.7%. Its deepest 1-year drawdown was 56.9%.

ADAG key facts

Asset type

Stock

Asset class

Equity

Inception date

02/09/2021

Distribution frequency

None

Last close

$2.06 (as of 2026-10-16)

Market cap

$138,315,289

Average volume

379601.0

Beta

0.537

Payout ratio

0.0%

EPS

$-0.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADAG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 56.9%.

Who may consider ADAG — and who may not

It is a weaker fit for investors who need monthly cash flow (ADAG does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ADAG

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions